SKIP TO CONTENT
30+/SKIN
← ACTIVESRECORD A-01FAMILY RETINOID

Tretinoin

All-trans-retinoic acid

ALSO — RETINOIC ACID, VITAMIN A ACID

A prescription retinoid used in different finished products for acne and particular photoaging indications. The vehicle, treatment goal and trial population matter alongside its concentration.

A REFERENCE STRENGTH IN THE RANGE RECORDED0.001% ——— 0.1%
0.05%

The marker is a representative concentration from the cited records. The bar includes approved and compounded preparations recorded here. It is not a recommended dose, a minimum effective strength or a claim that other concentrations are untested. Evidence depends on the vehicle, indication and trial population.

IDENTITY & RATINGSA
INCIAll-trans-retinoic acid
FAMILYRetinoid
MOL. WEIGHT300.44 g/mol
REFERENCE CONC.0.05%
RANGE SEEN0.001 – 0.1%
STATUSPRESCRIPTION ONLY
ACTS ATDERMIS
ONSET8–24 WK
STABILITYPHOTOLABILE — DEGRADES IN LIGHT AND AIR
TRIALS ON FILE5
IRRITATION INDEX6 / 10
STRATUM CORNEUMEPIDERMIS▸ DERMIS

The shaded band is the depth this molecule is understood to reach. Anything below it is out of scope, whatever the label says.

01

Mechanism

EVIDENCE GRADE A

Binds the retinoic acid nuclear receptors directly, with no conversion step. Reduces cohesiveness of follicular epithelial cells and microcomedone formation, increases keratinocyte turnover, and over months increases procollagen deposition in the papillary dermis.

HOUSE NOTES

  • The concentration marker is one reference from this register, not a minimum effective dose or a claim that all lower strengths are untested.
  • Evidence for one strength and vehicle cannot be transferred automatically to every compounded formula containing tretinoin.
  • An acne endpoint and a wrinkle endpoint answer different questions. Read the named product's indication and trial population.
  • TWYNEO contains tretinoin with benzoyl peroxide in a purpose-built formulation; this does not validate mixing separate products.

MEASURED ENDPOINTS

Fine facial wrinkling, any improvement+21%
24 WKREF-01
EGSS success, acne+9.6%
12 WKREF-13
Total lesion count reduction+22%
12 WKREF-23
Fine wrinkling, Fitzpatrick IV–VI-14%
24 WKREF-02
Application-site dryness, lotion vehicle-3%
12 WKREF-14

SUPPORTING RECORDS

  • Four multi-centre randomised trials, vehicle-controlled, on a comprehensive sun-avoidance programme

    N=559 · 24 WK · DOUBLE-BLIND

  • Multicentre randomised, vehicle-controlled

    N=820 · 12 WK · DOUBLE-BLIND

  • Randomised, vehicle-controlled

    N=143 · 12 WK · DOUBLE-BLIND

  • Single-centre randomised controlled trial in darkly pigmented, mostly African-American subjects

    N=107 · 24 WK · NOT STATED

  • Pooled safety analysis of two randomised, vehicle-controlled trials

    N=1550 · 12 WK · DOUBLE-BLIND

02

Layering

CONFLICTS & PAIRINGS
DO NOT LAYER
  • Other irritating treatments — review the complete regimen
  • Benzoyl peroxide — compatibility depends on the named formulation
  • Pregnancy — discuss an alternative with the clinician
PAIRS WITH
03

Reviewed in

11 REVIEWS
04

Comparing prescriptions

RESEARCH CHECKED · 13 SEP 2026

A service, a compound and a finished medicine are different records

A telehealth service can give access to several prescriptions. A custom-formula menu can list ingredients that a patient never receives. A manufactured product has a defined strength and vehicle. Start with the actual prescribed preparation before selecting evidence or comparing a price.

What to ask about a proposed formula

Request the exact ingredients, strengths, base, quantity and usable period, then ask why they fit the concern being treated. A higher percentage is not automatically an appropriate escalation, and an ingredient trial is not a test of every possible combination.

Compatibility and cost need product details

The current TWYNEO label describes separate encapsulation of its two actives and specific discard limits. That combination shows why a universal layering prohibition is too broad. Ask about the named products and storage instructions rather than inferring a regimen from the ingredient names alone.

Sources

  1. S-01TWYNEO — current manufacturer prescribing information

    February 2025 label names Mayne Pharma and a 30 g pump. Trial 1 success and difference figures in Table 4 conflict; that row is not charted here. Storage limits are product-specific. Checked 13 September 2026.

  2. S-02Agency — Night Renew Rx, formerly Future Formula

    Current name, $130 price, 24 g / 60-day supply, ingredient menu and formula-specific bases. Strength comparisons are not clinical outcome comparisons. Checked 13 September 2026.

  3. S-03FDA — understanding compounded-drug risks

    Compounded preparations do not undergo FDA premarket review for safety, effectiveness or quality; they can meet individual medical needs. Checked 13 September 2026.

  4. S-04American Academy of Dermatology — pregnancy skin care

    Guidance to avoid retinoids and hydroquinone during pregnancy. Breastfeeding decisions need separate clinician advice. Checked 13 September 2026.

EVERY FIGURE HERE RESOLVES TO A RECORD IN THE EVIDENCE REGISTER. NOT MEDICAL ADVICE.
THE DRAW · NO. 01

Win a year of
prescription skincare

One reader gets a 12 months CoreAge Rx derm plan — the compounded, physician-reviewed subscription we take apart in the register. Worth $780. Leave an address and you are entered.

PRIZE
12 MONTHS OF COREAGE RX
VALUE
$780 — $64.99/MO × 12
ENTRY
ONE EMAIL ADDRESS

VALUE IS THE PUBLISHED $64.99/MONTH SUBSCRIPTION PRICE OVER TWELVE MONTHS, AS RECORDED IN R-10. NO PURCHASE NECESSARY. WE REVIEW COREAGE RX — WE DO NOT SELL IT.

DEPTH 000%
THE DRAW · ONE READER

Win a year of
prescription skincare

One reader gets a 12 months CoreAge Rx derm subscription — compounded, physician-reviewed, delivered. See the product records in our review register.

VALUE$780
TERM12 MONTHS$64.99/MO × 12

VALUE IS THE PUBLISHED $64.99/MONTH SUBSCRIPTION PRICE OVER TWELVE MONTHS, AS RECORDED IN R-10. NO PURCHASE NECESSARY. WE REVIEW COREAGE RX — WE DO NOT SELL IT.